Pheochromocytoma/Paraganglioma research hub
3 indexed studies · 3 currently recruiting
- recruitingPHASE2
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
This study is testing a new medicine called belzutifan for certain types of advanced cancers, including rare adrenal gland, gut, and kidney cancers. We want to see how well it works and if it's safe for people aged 12 and over.
United States · Australia · Canada - recruitingPHASE2
An Experimental Study of Belzutifan Impact on Catecholamine Metabolism
This study looks at how a drug called Belzutifan affects chemicals (adrenaline and noradrenaline) in people with a rare growth condition called pheochromocytoma or paraganglioma. We want to see if the drug changes how these chemicals are made and processed in the body over five days.
United Kingdom - not yet recruiting
A Comparison of [68Ga]DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine Malignancies
Researchers are comparing two types of scans called PET/CT to see which is better at finding and checking on neuroendocrine tumours (NETs). They want to know if a newer scan, using a tracer called 18F-AmBF3-TATE, works as well as or better than the standard scan, which uses 68Ga-DOTATATE.
Canada